{"id":"https://openalex.org/W2001979850","doi":"https://doi.org/10.3389/fonc.2012.00147","title":"Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective","display_name":"Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective","publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2001979850","doi":"https://doi.org/10.3389/fonc.2012.00147","mag":"2001979850","pmid":"https://pubmed.ncbi.nlm.nih.gov/23112955","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3482933"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2012.00147","doi":"https://doi.org/10.3389/fonc.2012.00147","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2012.00147","pdf_url":"https://www.frontiersin.org/articles/10.3389/fonc.2012.00147/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","datacite","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/articles/10.3389/fonc.2012.00147/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101449078","display_name":"Roberto G\u00f3mez","orcid":"https://orcid.org/0000-0003-4979-0034","observed_orcids":["https://orcid.org/0000-0003-4979-0034"]},"institutions":[{"id":"https://openalex.org/I4210122045","display_name":"Elea (Argentina)","ror":"https://ror.org/032wae568","country_code":"AR","type":"company","lineage":["https://openalex.org/I4210122045"]}],"countries":["AR"],"is_corresponding":true,"raw_author_name":"Roberto E. G\u00f3mez","raw_affiliation_strings":["Medical Affairs, Laboratorio ELEA SACIFyA Buenos Aires, Argentina","Laboratorio ELEA SACIFyA, Medical Affairs, Sanabria 2353, Buenos Aires, C1417AZE, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs, Laboratorio ELEA SACIFyA Buenos Aires, Argentina","institution_ids":["https://openalex.org/I4210122045"]},{"raw_affiliation_string":"Laboratorio ELEA SACIFyA, Medical Affairs, Sanabria 2353, Buenos Aires, C1417AZE, Argentina","institution_ids":["https://openalex.org/I4210122045"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069585801","display_name":"Mar\u00eda Laura Ardig\u00f3","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210122045","display_name":"Elea (Argentina)","ror":"https://ror.org/032wae568","country_code":"AR","type":"company","lineage":["https://openalex.org/I4210122045"]}],"countries":["AR"],"is_corresponding":false,"raw_author_name":"Maria L. Ardigo","raw_affiliation_strings":["Laboratorio ELEA SACIFyA, Clinical Research, Sanabria 2353, Buenos Aires, C1417AZE, Argentina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratorio ELEA SACIFyA, Clinical Research, Sanabria 2353, Buenos Aires, C1417AZE, Argentina","institution_ids":["https://openalex.org/I4210122045"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5101449078"],"corresponding_institution_ids":["https://openalex.org/I4210122045"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.7796,"has_fulltext":true,"cited_by_count":10,"citation_normalized_percentile":{"value":0.6773637,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"2","issue":null,"first_page":"147","last_page":"147"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.8939999938011169,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.8939999938011169,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.07769999653100967,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.01940000057220459,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-idiotypic-antibodies","display_name":"anti-idiotypic antibodies","score":0.9929999709129333},{"id":"https://openalex.org/keywords/cancer-vaccines","display_name":"cancer vaccines","score":0.9240000247955322},{"id":"https://openalex.org/keywords/active-immunotherapy","display_name":"active immunotherapy","score":0.9559999704360962},{"id":"https://openalex.org/keywords/pharmaceutical-industry","display_name":"pharmaceutical industry","score":0.6899999976158142},{"id":"https://openalex.org/keywords/clinical-trial-design","display_name":"clinical trial design","score":0.7070000171661377},{"id":"https://openalex.org/keywords/regulatory-challenges","display_name":"regulatory challenges","score":0.4519999921321869}],"concepts":[{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6596516370773315},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5909537076950073},{"id":"https://openalex.org/C12713177","wikidata":"https://www.wikidata.org/wiki/Q1900281","display_name":"Perspective (graphical)","level":2,"score":0.5737023949623108},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5329165458679199},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5218916535377502},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.4892277717590332},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.4686179757118225},{"id":"https://openalex.org/C2778378633","wikidata":"https://www.wikidata.org/wiki/Q2378309","display_name":"Cancer vaccine","level":4,"score":0.46282655000686646},{"id":"https://openalex.org/C3020340455","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Cancer drugs","level":3,"score":0.4541144371032715},{"id":"https://openalex.org/C3019816032","wikidata":"https://www.wikidata.org/wiki/Q2575340","display_name":"Cancer treatment","level":3,"score":0.4494676887989044},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3407876491546631},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.17483225464820862},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13060486316680908},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.11247330904006958},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.0}],"mesh":[],"locations_count":8,"locations":[{"id":"doi:10.3389/fonc.2012.00147","doi":"https://doi.org/10.3389/fonc.2012.00147","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2012.00147","pdf_url":"https://www.frontiersin.org/articles/10.3389/fonc.2012.00147/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2476521","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3482933","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:23112955","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23112955","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:3482933","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3482933/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Oncol","raw_type":"Text"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.794.1685","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.794.1685","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/b4/a1/fonc-02-00147.PMC3482933.pdf","raw_type":"text"},{"id":"pmh:oai:doaj.org/article:4e2093fadb8f4911b0d7578b09402b27","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/4e2093fadb8f4911b0d7578b09402b27","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 2 (2012)","raw_type":"article"},{"id":"doi:10.60692/mjqzr-y2232","doi":"https://doi.org/10.60692/mjqzr-y2232","is_oa":true,"landing_page_url":"https://doi.org/10.60692/mjqzr-y2232","pdf_url":null,"source":{"id":"https://openalex.org/S7407051682","display_name":"Greater South Information System","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"},{"id":"doi:10.60692/zta3v-y7k48","doi":"https://doi.org/10.60692/zta3v-y7k48","is_oa":true,"landing_page_url":"https://doi.org/10.60692/zta3v-y7k48","pdf_url":null,"source":{"id":"https://openalex.org/S7407051682","display_name":"Greater South Information System","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"doi:10.3389/fonc.2012.00147","doi":"https://doi.org/10.3389/fonc.2012.00147","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2012.00147","pdf_url":"https://www.frontiersin.org/articles/10.3389/fonc.2012.00147/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.8999999761581421,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2001979850.pdf","grobid_xml":"https://content.openalex.org/works/W2001979850.grobid-xml"},"referenced_works_count":29,"referenced_works":["https://openalex.org/W1496563114","https://openalex.org/W1591828651","https://openalex.org/W1930259341","https://openalex.org/W1970398250","https://openalex.org/W1982131071","https://openalex.org/W1983139088","https://openalex.org/W2028697741","https://openalex.org/W2033195789","https://openalex.org/W2035446451","https://openalex.org/W2054873994","https://openalex.org/W2067844377","https://openalex.org/W2087078460","https://openalex.org/W2093783864","https://openalex.org/W2102895446","https://openalex.org/W2107773664","https://openalex.org/W2109688168","https://openalex.org/W2116075163","https://openalex.org/W2125385057","https://openalex.org/W2129268236","https://openalex.org/W2133254722","https://openalex.org/W2134121541","https://openalex.org/W2153790270","https://openalex.org/W2155020307","https://openalex.org/W2164374194","https://openalex.org/W2315899558","https://openalex.org/W2398786227","https://openalex.org/W4255557122","https://openalex.org/W4285719527","https://openalex.org/W6600269950"],"related_works":["https://openalex.org/W7098152668","https://openalex.org/W2127555836","https://openalex.org/W2071179885","https://openalex.org/W2360635851","https://openalex.org/W192002184","https://openalex.org/W1965978263","https://openalex.org/W7005132223","https://openalex.org/W3097546114","https://openalex.org/W2091007960","https://openalex.org/W2411257614"],"abstract_inverted_index":{"Active":[0],"immunotherapy":[1],"is":[2,41,75,78],"an":[3,118],"interesting":[4],"field":[5],"from":[6,106],"the":[7,12,18,44,61,87,97,107,114],"industry's":[8,108],"perspective":[9],"and":[10,17,25,39,71,83,110],"in":[11,27,43,57,113],"last":[13],"years,":[14],"regulatory":[15],"agencies":[16],"medical":[19],"community":[20],"have":[21],"showed":[22],"renewed":[23],"expectations":[24],"interest":[26],"cancer":[28,92,100],"vaccines.":[29,93],"The":[30],"development":[31,62,88],"of":[32,47,63,89,99,116],"new":[33,73],"immune":[34],"therapies":[35],"offers":[36],"many":[37],"challenges,":[38],"this":[40],"reflected":[42],"small":[45],"number":[46],"phase":[48],"III":[49],"trials":[50,59],"showing":[51],"clear":[52],"benefits.":[53],"Traditional":[54],"concepts":[55],"applied":[56],"clinical":[58],"for":[60,69],"chemotherapeutic":[64],"agents":[65],"may":[66],"be":[67],"inadequate":[68],"immunotherapies":[70],"a":[72],"paradigm":[74],"emerging.":[76],"It":[77],"possible":[79],"that":[80],"organized":[81],"efforts":[82],"funding":[84],"will":[85],"accelerate":[86],"therapeutically":[90],"effective":[91],"This":[94],"article":[95],"reviews":[96],"attributes":[98],"vaccines":[101],"which":[102],"make":[103],"them":[104],"attractive":[105],"perspective,":[109],"focuses":[111],"especially":[112],"characteristics":[115],"Racotumomab,":[117],"anti-idiotype":[119],"antibody":[120],"vaccine.":[121]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":2}],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2016-06-24T00:00:00"}